Gufic Biosciences: Special Window for Share Transfer & Dematerialization
Gufic Biosciences announces a special window for re-lodging transfer deeds and dematerializing physical shares. The window is open from February 05, 2026, to February 04, 2027. This applies to transfers executed before April 01, 2019. Transferred shares will have a one-year lock-in period.
This is a routine regulatory compliance announcement providing a facility for shareholders. It does not involve any immediate financial implications or significant corporate actions that would impact the company's operations or stock price.
The announcement is a procedural update regarding a special window for share transfers and dematerialization, providing information to shareholders. It does not contain any financial performance details or strategic shifts that would indicate a positive or negative sentiment.
Gufic Biosciences Limited has announced the commencement of a special window for the re-lodgement of transfer deeds related to physical securities and for dematerialization. This initiative, in line with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, allows shareholders to transfer physical securities and dematerialize them. The facility is open from February 05, 2026, to February 04, 2027.
The special window is applicable for physical securities where transfer deeds were executed before April 01, 2019, including cases where previous transfer requests were rejected or returned. Shareholders must submit original certificates along with transfer deeds and supporting documents. Securities transferred under this window will be credited to the transferee's demat account and will be under a one-year lock-in period from the date of transfer registration. They cannot be transferred or lien-marked during this period.
Shareholders seeking further assistance or information regarding this process can contact the company's Registrar and Transfer Agent, MUFG lntime India Private Limited, or Gufic Biosciences Limited's corporate office.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.